These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32389792)

  • 1. Characterization of fosfomycin heteroresistance among multidrug-resistant Escherichia coli isolates from hospitalized patients in Rio de Janeiro, Brazil.
    Campos ACDC; Andrade NL; Couto N; Mutters NT; de Vos M; Rosa ACP; Damasco PV; Lo Ten Foe JR; Friedrich AW; Chlebowicz-Flissikowska MA; Rossen JWA
    J Glob Antimicrob Resist; 2020 Sep; 22():584-593. PubMed ID: 32389792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased cyclic-AMP caused by ATP contributes to fosfomycin heteroresistance in avian Escherichia coli.
    Zhao B; Han H; He K; Hou WF; Liang YL; Cui JL; He DD; Hu GZ; Liu JH; Yuan L
    J Antimicrob Chemother; 2022 Dec; 78(1):216-224. PubMed ID: 36374526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
    Bi W; Li B; Song J; Hong Y; Zhang X; Liu H; Lu H; Zhou T; Cao J
    Int J Antimicrob Agents; 2017 Jul; 50(1):29-34. PubMed ID: 28456703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experiences in fosfomycin susceptibility testing and resistance mechanism determination in Escherichia coli from urinary tract infections in the UK.
    Cottell JL; Webber MA
    J Med Microbiol; 2019 Feb; 68(2):161-168. PubMed ID: 30543320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases.
    Bahramian A; Eslami G; Hashemi A; Tabibi A; Heidary M
    Acta Microbiol Immunol Hung; 2018 Mar; 65(1):15-25. PubMed ID: 29137487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Fosfomycin Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolates from Human and Pig in Taiwan.
    Tseng SP; Wang SF; Kuo CY; Huang JW; Hung WC; Ke GM; Lu PL
    PLoS One; 2015; 10(8):e0135864. PubMed ID: 26280832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.
    Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J
    J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Molecular Characterization of
    Campos ACC; Andrade NL; Ferdous M; Chlebowicz MA; Santos CC; Correal JCD; Lo Ten Foe JR; Rosa ACP; Damasco PV; Friedrich AW; Rossen JWA
    Front Microbiol; 2018; 9():243. PubMed ID: 29503639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of O25b-ST131 clone and fosfomycin resistance in urinary Escherichia coli isolates and their relation to CTX-M determinant.
    Demirci-Duarte S; Unalan-Altintop T; Eser OK; Cakar A; Altun B; Sancak B; Gur D
    Diagn Microbiol Infect Dis; 2020 Sep; 98(1):115098. PubMed ID: 32603974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Efficacy of Six Alternative Antibiotics against Multidrug Resistant Escherichia Coli and Klebsiella Pneumoniae from Urinary Tract Infections.
    Chen YT; Ahmad Murad K; Ng LS; Seah JT; Park JJ; Tan TY
    Ann Acad Med Singap; 2016 Jun; 45(6):245-50. PubMed ID: 27412057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of hypermutation to fosfomycin heteroresistance in Escherichia coli.
    Portillo-Calderón I; Ortiz-Padilla M; Rodríguez-Martínez JM; de Gregorio-Iaria B; Blázquez J; Rodríguez-Baño J; Pascual A; Docobo-Pérez F
    J Antimicrob Chemother; 2020 Aug; 75(8):2066-2075. PubMed ID: 32443144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological cost of fosfomycin resistance in Escherichia coli in a murine model of urinary tract infection.
    Pourbaix A; Guérin F; Lastours V; Chau F; Auzou M; Boulley E; Cattoir V; Fantin B
    Int J Med Microbiol; 2017 Dec; 307(8):452-459. PubMed ID: 28986014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake.
    Martín-Gutiérrez G; Docobo-Pérez F; Rodriguez-Beltrán J; Rodríguez-Martínez JM; Aznar J; Pascual A; Blázquez J
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of fosfomycin resistance among ESBL-producing Escherichia coli isolates in the community, Switzerland.
    Mueller L; Cimen C; Poirel L; Descombes MC; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):945-949. PubMed ID: 30877486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
    Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissemination of plasmid-mediated fosfomycin resistance fosA3 among multidrug-resistant Escherichia coli from livestock and other animals.
    Ho PL; Chan J; Lo WU; Law PY; Li Z; Lai EL; Chow KH
    J Appl Microbiol; 2013 Mar; 114(3):695-702. PubMed ID: 23216653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against
    Abbott IJ; van Gorp E; Wijma RA; Meletiadis J; Roberts JA; Mouton JW; Peleg AY
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.